Each year approximately 2 billion chest X-rays are performed globally. They are fast, noninvasive, and relatively inexpensive radiological examinations for front-line diagnostics in outpatient, emergency, or community settings.
Be it serendipitous screening, opportunistic detection, or incidental identification, there is potential for AI incorporated into CXR to screen patients for disease when they are getting an unrelated medical examination.
AI can find these abnormalities and flag them to clinicians as a suspicious finding for further investigation.
Indeed, only 5.8% of eligible ex-smoking Americans undergo CT-based lung cancer screening.
Early global studies into the power of AI for incidental pulmonary nodules (IPNs) shows exciting promise.
The
qXR-LN chest X-ray AI algorithm from Qure.ai is raising the bar for incidental pulmonary nodule detection. In a retrospective study performed on missed or mislabelled US CXR data, qXR-LN achieved an impressive negative predictive value of 96% and an AUC score of 0.99 for detection of pulmonary nodules.
The FDA-cleared solution serves as a crucial second reader, assisting in the review of chest radiographs on the frontal projection.
By harnessing the power of AI for opportunistic lung cancer surveillance, healthcare providers can adopt a proactive approach to early detection, without significant new investment, and ultimately improving patient survival rates.